KLK3 and pachyonychia congenita: A previous study also reported 15 men with deficient mismatch repair (dMMR) and/or MSI-high metastatic PC who received pembrolizumab monotherapy and had sufficient clinical data to evaluate PSA response, among which seven (47%) showed a decline in PSA values >90% (Graham et al. 2020).